Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

• Published in: The New England journal of medicine Vol. 371; no. 7; pp. 635 - 645
• Main Authors: DiazGranados, Carlos A, Dunning, Andrew J, Kimmel, Murray, Kirby, Daniel, Treanor, John, Collins, Avi, Pollak, Richard, Christoff, Janet, Earl, John, Landolfi, Victoria, Martin, Earl, Gurunathan, Sanjay, Nathan, Richard, Greenberg, David P, Tornieporth, Nadia G, Decker, Michael D, Talbot, H. Keipp
• Format: Journal Article
• Language: English
• Published: Waltham, MA Massachusetts Medical Society 14.08.2014
• Subjects: Age; Aged; Antibodies, Viral - blood; Biological and medical sciences; Chronic Disease; Double-Blind Method; Drug dosages; Female; General aspects; Hemagglutination; Hemagglutinins; Human viral diseases; Humans; Immunogenicity; Infectious diseases; Influenza; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - immunology; Influenza, Human - prevention & control; Intention to Treat Analysis; Male; Medical sciences; Motivation; Older people; Orthomyxoviridae - immunology; Vaccination; Vaccines; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - immunology; Viral diseases; Viral diseases of the respiratory system and ent viral diseases; United States > US; California; Human; Infection; Medicine; Prevention; Immunoprophylaxis; Viral disease; Influenza; Adult; Vaccine; High dose; Comparative study; Standards
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1315727

Improving the efficacy of influenza vaccination in older adults is a challenge. In this randomized clinical trial, a high-dose influenza vaccine was shown to be more effective than a standard-dose vaccine in the prevention of laboratory-confirmed influenza. Between 1990 and 1999, seasonal influenza caused an average of 36,000 deaths and 226,000 hospitalizations per year in the United States. 1 – 3 Adults 65 years of age or older are particularly vulnerable to complications associated with influenza and account for most seasonal influenza–related hospitalizations and deaths. 2 , 3 Although vaccination currently represents the most effective intervention against influenza and associated complications, 3 , 4 antibody response and protection elicited by the vaccine are lower among persons 65 years of age or older than among younger adults. 5 – 7 Strategies to improve antibody responses to influenza vaccine in the older population, such as increasing the . . .